Authored By: Sarah
11 Jul 2024

 Head And Neck Cancer Treatment Market to grow by USD 7120.5 million between 2024-2028

According to a research report “ Head And Neck Cancer Treatment Market” by Route Of Administration (Injectable, Oral) Therapy (Immunotherapy, Targeted therapy, Chemotherapy) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 7120.5 million at a CAGR of  13.64% during the forecast period. The head and neck cancer market encompasses treatments for malignancies affecting the oral cavity, pharynx, larynx, paranasal sinuses, nasal cavity, and salivary glands. Primarily driven by squamous cell carcinoma (SCC), which accounts for approximately 90% of cases and is predominantly diagnosed late among heavy alcohol and tobacco users, this market segment represents around 4% of all cancer cases in the US. With a global incidence rate of about 500,000 new cases annually, the demand for effective head and neck cancer treatments continues to grow..

Browse market data tables, figures, and in-depth TOC on “Head And Neck Cancer Treatment Market” by Route Of Administration (Injectable, Oral) Therapy (Immunotherapy, Targeted therapy, Chemotherapy) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028.

 View detailed Table of Content- Click here

By Route Of Administration, the Injectable segment is projected to dominate the market size in 2024.

In the Head and Neck Cancer Treatment Market, immunotherapy has emerged as a significant trend, with substances like monoclonal antibodies, vaccines, and immune checkpoint inhibitors boosting the immune system to target cancer cells. Notably, immune checkpoint inhibitors, such as pembrolizumab and nivolumab, have demonstrated substantial benefits, disrupting the interaction between cancer cells and immune cells, thereby enhancing survival rates and improving quality of life for advanced-stage patients. Clinical trials underscore their efficacy, making these inhibitors a valuable investment in the evolving cancer treatment landscape.

By Therapy, Immunotherapy  segment is expected to hold the largest market size for the year 2024.

The Head and Neck Cancer Treatment Market encompasses the use of injectable drugs, a segment that offers convenience and efficacy through direct bloodstream administration. Notable drugs in this category include chemotherapy agents, such as cisplatin. Cisplatin, a widely-used chemotherapy agent, is instrumental in treating head and neck cancer through DNA damage and growth inhibition. Its intravenous administration ensures targeted and efficient drug delivery to cancer cells.

North America is forecasted to hold the largest market size by region in 2024.

In the dynamic business landscape, the Head and Neck Cancer Treatment Market presents significant growth opportunities. With a steadily rising prevalence rate and increasing awareness, this sector is poised for expansion. Key players are investing in innovative technologies, such as immunotherapies and targeted therapies, to cater to evolving patient needs. The market's robust growth is further fueled by strategic collaborations, regulatory approvals, and favorable reimbursement policies.

The Head And Neck Cancer Treatment Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Amgen Inc.
  • AstraZeneca Plc
  • Ayala Pharmaceuticals Inc.
  • Bristol Myers Squibb Co.
  • Debiopharm International SA
  • Eli Lilly and Co.
  • Incyte Corp.
  • Merck and Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

In the realm of head and neck cancer treatment, the market is witnessing significant advancements with the development of various therapeutic options. These include **Rozlytrek (entrectinib)**, an FDA-approved medication for ROS1-positive advanced solid tumors, including those in the head and neck region. Another groundbreaking therapy is **Tecentriq (atezolizumab)**, an immunotherapeutic agent that targets programmed death-ligand 1 (PD-L1) and has shown promise in treating various types of malignant tumors, including those affecting the larynx, salivary glands, mouth, nose, and throat. Moreover, the pipeline is enriched with **Tiragolumab**, an anti-TIGIT monoclonal antibody, and **Tipifarnib**, a farnesyltransferase inhibitor. These systemic drug therapies, along with Merck/Debiopharm's Xevinapant, an immunosuppressive agent, are essential components of the nonsurgical therapeutic arsenal. It is crucial to note that these therapies, as well as **chemotherapy**, are typically administered as outpatient visits and may require patients to abstain from alcohol consumption for optimal efficacy. Surgical treatment remains an essential part of the therapeutic approach, but the growing emphasis on nonsurgical therapies is transforming the head and neck cancer treatment landscape.

Market Research Overview

In the realm of oncology, the Head and Neck Cancer Treatment Market encompasses a broad spectrum of interventions aimed at managing various malignant tumors affecting the nasal cavity, paranasal sinuses, pharynx, oral cavity, larynx, and salivary glands. This market includes a diverse range of therapeutic modalities, such as immunosuppressive drugs like Dostarlimab (Jemperli), Nivolumab (Opdivo), and Pembrolizumab (Keytruda), which are part of the immunotherapy segment and function as PD-L1 inhibitors. Additionally, the targeted therapy segment comprises tyrosine kinase inhibitors, such as Tipifarnib (Farnesyltransferase Inhibitor), and monoclonal antibodies, like Zalutumumab, Panitumumab, and Nimotuzumab. Nonsurgical therapeutics, such as Merck/Debiopharm's Xevinapant, and immunosuppressive agents, are also integral components of this market. The sales channel for these treatments extends to retail pharmacies, including Walgreens stores, CVS Specialty, Accredo, and Humana specialty pharmacy. Patients may also receive systemic drug therapies, such as Axitinib (Inlyta), Lapatinib, Dacomitinib, Gefitinib, and Erlotinib, as well as combination therapies and radiation therapy. The biopharmaceutical industry continues to invest in the development of pipeline drugs to address the unmet needs in head and neck cancer treatment, driven by the increasing awareness of disease consciousness and healthcare expenditure. Smoking and alcohol consumption are significant risk factors for head and neck cancers, and the internet serves as a crucial sales channel for disseminating information and facilitating access to these treatments.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio